Beam Therapeutics
NEWS
Beam Therapeutics has recently unveiled a new CRISPR base editing tool to target sickle cell mutations, a promising approach that holds substantial clinical value for patients with these blood disorders.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers and Shakers.
The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with sickle cell disease and beta-thalassemia.
Beam, which is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019, filed its IPO plans with the U.S. Securities and Exchange Commission on Friday.
Biotech and pharma companies strengthen their leadership teams and boards of directors with this week’s appointments.
There is, thankfully, no age limit on innovation—you can do it at any age. But for many, “young,” counts as under 30, sometimes under 35, or even under 40, at least in terms of putting together lists of scientific innovators.
Both companies said they plan to work together in order to strengthen their competitive positions.
Biopharma companies add new leaders to executive roles and boards of directors.
Beam Therapeutics is one of BioSpace’s NextGen Bio “Class of 2019” Life Science Startups to Watch in 2019.
JOBS
IN THE PRESS